The evaluation of serum lipid profile and Apolipoprotein C-1 in the Iranian patients of Oral Squamous Cell Carcinoma
The evaluation of serum lipid profile and Apolipoprotein C-1 in the Iranian patients of Oral Squamous Cell Carcinoma

Cover Page Footnote
This article has been extracted from the thesis written by Ms. Walaa Alazzawi (Registration No.:233).

This original articles is available in BioMedicine: https://www.biomedicinej.com/biomedicine/vol12/iss3/6
The evaluation of serum lipid profile and apolipoprotein C-1 in the Iranian patients of Oral Squamous Cell Carcinoma

Walaa Alazzawi a,1, Zahra Shahsavari a,1, Hanieh Babaei b, Hadis Firouzpour a, Abbas Karimi c, Afsaneh Goudarzi a,1

a Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
b Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
c Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The key role of apolipoprotein C-1 (ApoC-1) is reported in breast, pancreas and lung cancer. However, no information is available on potential difference of ApoC-1 between OSCC patients and healthy individuals. This work aimed to examine the serum ApoC-1 level as well as lipid profile values between OSCC patients and healthy control groups.

Material and methods: In this study, 44 blood samples from 22 OSCC patients and 22 healthy individuals were collected to determine the values of lipid profile and ApoC-1 concentration using colorimetric method and Enzyme-Linked Immunosorbent Assay (ELISA), respectively.

Results: A significant decrease in serum lipid profile and ApoC-1 concentration was observed between OSCC and healthy control groups (P = 0.001).

Conclusion: Our results confirm the previous findings on the significant differences of lipid profile between OSCC and controls, also show the lower serum level of ApoC-1 in OSCC as compared to the controls. Future studies would further elaborate the association of ApoC-1 with OSCC.

Keywords: Oral squamous cell carcinoma, Serum lipid profile, Serum ApoC1

1. Introduction

Despite recent progress in therapeutic strategies, the outcome of Oral Squamous Cell Carcinoma (OSCC) patients has not improved yet [1]. OSCC accounts for more than 90% of all neoplasms in the oral cavity with a 5-year survival rate less than 50% [2]. The diagnosis of OSCC occurs at late stage and is more common in developing than developed countries [3]. The major cell components are lipids which have indispensable roles in growing and dividing of normal and malignant tissues [4]. High rate of lipid peroxidation releases peroxide radicals which attack essential components of the cell membrane thus increase the demand on lipids including total cholesterol, lipoproteins and triglycerides for synthesis of new membrane [5]. Recent studies have shown the association of altered lipid profile with head and neck squamous cell carcinoma, breast cancer, ovarian tumours and colorectal cancer [6–9]. Apolipoproteins are key proteins in regulation of lipoprotein metabolism, their basic functions are lipid delivery, the activation or inhibition of enzymes involved in metabolism of lipoproteins and as ligands to recognize the lipoproteins’ receptors [10]. Recently, published results support abnormal expression of apolipoproteins in tumours which is related to the prognosis of patients [11]. Hence, the attention has focused on the association of apolipoprotein family in tumours’ incidence and progression. ApoC-1 which belongs to

Received 7 January 2022; accepted 6 April 2022.
Available online 01 September 2022

* Corresponding author.
E-mail address: Afsaneh.goudarzi@sbmu.ac.ir (A. Goudarzi).
1 Co-first authors.
apolipoprotein family contributes to the Chylomicron, VLDL and HDL-C metabolism [12] and its involvement in progression of several diseases including diabetes, polycystic ovary syndrome, Alzheimer’s disease and glomerulosclerosis has been shown [13–15]. Although numerous studies revealed that ApoC-1 is associated with the tumour progression but the exact underlying mechanism and signaling pathway of ApoC-1 in tumours is still unclear [16–18]. The correlation of high tissue expression and high preoperative serum concentration of ApoC-1 with poor prognosis of pancreatic cancer patients has been reported by Li and colleagues [18]. Also, the diagnostic ability of overexpressed ApoC-1 has been reported to distinguish triple negative breast cancer (TNBC) from non-TNBC (NTNBC) and is considered as a potential prognostic biomarker for TNBC [19]. The upregulated mRNA and protein expression levels of ApoC-1 in prostate cancer tissue is correlated with survival of prostate cancer cells by inhibiting apoptosis, also the increased serum level of ApoC-1 is associated with the prognosis of prostate cancer patients [17]. The significant decrease in serum levels of ApoC-1 has been reported in colorectal cancer, NSCLC [11,20], papillary thyroid carcinoma [21] and child nephroblastoma [22]. However, the serum level and role of ApoC-1 in OSCC remain elusive. In this experimental study, we sought to investigate and compare the serum lipid profile and ApoC-1 levels of OSCC patients with healthy individuals.

2. Materials and methods

2.1. Subjects

The serum samples of 22 patients diagnosed with OSCC who had surgery from January 2019 to April 2021 were provided from a Pathology laboratory (School of Dentistry, Cancer Institute Hospital) and two hospitals (Bahman and Shariati hospitals) of Tehran, Iran. The clinicopathological description of study groups are shown in Table 1. All patients had a histologically biopsy proven diagnosis for OSCC, belonged to an age group of 38–84 years. Patients who had other diseases or were under treatment with medications that could affect their lipid profile (diabetes, liver failure or thyroid disorders) were excluded. 22 healthy subjects of control group were age- and gender-matched without any history of major illness in the past. The tumours were graded histologically to grade I (well-differentiated), grade II (moderately differentiated) and grade III (poorly differentiated) based on WHO criteria. Tumour staging has been performed according to the

| Characteristics          | OSCC patients (n = 22) | Healthy controls (n = 22) |
|--------------------------|------------------------|---------------------------|
| Age Mean (y)             | 63                     | 62.4                      |
| Age (y)                  |                         |                           |
| <60                      | 7                      | 10                        |
| >60                      | 15                     | 12                        |
| Sex                      |                         |                           |
| Female                   | 11                     | 8                         |
| Male                     | 11                     | 14                        |
| Grade                    |                         |                           |
| Grade I                  | 13                     | –                         |
| Grade II                 | 7                      | –                         |
| Grade III                | 2                      | –                         |
| Stage                    |                         |                           |
| I                        | 3                      | –                         |
| II                       | 5                      | –                         |
| III                      | 6                      | –                         |
| IV                       | 6                      | –                         |
| Tumour size              |                         |                           |
| ≤3.5 cm                  | 10                     | 10                        |
| >3.5 cm                  | 10                     |                           |
| Death                    |                         |                           |
| Yes                      | 1                      | 0                         |
| No                       | 21                     | 22                        |
| Vascular invasion        |                         |                           |
| Yes                      | 6                      | –                         |
| No                       | 8                      | –                         |
| Perineural invasion      |                         |                           |
| Yes                      | 7                      | –                         |
| No                       | 7                      | –                         |
| Tumour subsites          |                         |                           |
| Oral cavity              | 1                      | –                         |
| Tongue                   | 5                      | –                         |
| Mouth floor              | 1                      | –                         |
| Lip/Buccal mucosa        | 9                      | –                         |
| Maxilla                  | 2                      | –                         |
| Mandible                 | 2                      | –                         |
| Palate                   | 2                      | –                         |

American Joint Committee on Cancer (AJCC). Clinical information including age, gender, tumour location were obtained from the information file of patients. This study was performed at Clinical Biochemistry department of Shahid Beheshti University of Medical Sciences (SBMU) under ethical approval of SBMU: IR.SBMU.MSP.REC.1400.168.

2.2. Serum lipid profile assessment

The lipid profile tests measure serum total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, and VLDL. After a 12–14 h overnight fasting, 5 ml of blood sample was collected under aseptic precautions in Serum Separator Tubes. To prepare the serum, the collected blood samples were clotted for 1 h and then centrifuged for 10 min, 3000 rpm at room temperature. The serum samples were stored in the freezer at −80 °C until measurements. The serums were then analyzed for lipid profile tests by
the commercially available kits, Cholesterol (Pars Azmoon, Iran), Triglyceride (biorexfars, Iran) and HDL-C (PishtazTeb, Iran) using a biochemistry autoanalyzer (BS-200 E, mindray, USA). The levels of LDL-C and VLDL were calculated by the following formula:

\[
LDL-C = (0.94 \times \text{Total Cholesterol}) - (0.94 \times \text{HDL-C}) - (0.19 \times \text{Triglyceride})
\]

\[
VLDL = \frac{\text{TG}}{5}
\]

### 2.3. Serum ApoC-1 measurement

Concentrations of ApoC-1 in serum samples of OSCC patients and healthy individuals were determined by commercially ELISA kit (Invitrogen, # EHAPOC1) following the manufacturer's protocol. In brief, the wells in ELISA plate were coated with 100 µl of standards (concentrations from 3.2 to 50,000 pg/ml of ApoC-1) and samples (diluted with sample diluents buffer in a proportion of 1/10,000) and incubated 2.5 h at room temperature. Next, plate contents were discarded and 300 µl of the Streptavidin–HRP solution was added to each well and incubated 1 h at room temperature with gentle shaking and then the contents were removed and washed four times with 1X wash buffer. After washing, 100 µl of the TMB solution was added to each well and incubated 45 min at room temperature. Next, the solution was removed and each well was washed four times with 1X wash buffer. After washing, 100 µl of the stop solution to each well was immediately read at 450 nm. The standard curve was generated using curve-fitting software and Apo-C1 concentrations of unknown samples were determined from this standard curve.

### 2.4. Statistical analysis

Data analysis was performed using GraphPad Prism version 6 and data are expressed as mean ± standard deviation (SD). Statistical analysis was done using the ANOVA test and unpaired t-test. Correlation coefficients were calculated using the two-tailed Pearson's correlation analysis. In all the above tests, P-value < 0.05 was taken to be statistically significant.

### 3. Results

#### 3.1. Decreased serum levels of lipid profile in OSCC patients compared to healthy individuals

In this study, a total of 11 male and 11 female patients with median age of 63 years were included, of them 4.54% patients had lesion on oral cavity, 9.09% on maxilla, 22.72% on tongue, 4.54% on mouth floor, 40.9% on lip/buccal mucosa, 9.09% on palate and 9.09% on mandible. 59.09% patients were graded as grade I, 31.81% grade II and 9.09% grade III. To compare the serum lipid profile between the OSCC patients and controls, the mean and P-values of all the serum lipid profile values were calculated and compared. A Significant decrease in serum cholesterol (P = 0.000002), triglyceride (P = 0.038), HDL-C (P = 6.65E-10), LDL-C (P = 0.011) and VLDL (P = 0.038) concentrations was found in OSCC patients compared to the healthy individuals (Fig. 1) which confirmed previous reports by [4,25]. Next, we compared the values of all the lipid profile with the clinical and pathological features of patients including tumour subsite, tumour grade and stage (Tables 2–4). To this end, OSCC patients were divided in three groups of well differentiated (grade I), moderately differentiated (grade II) and poorly differentiated (grade III). A significant cholesterol reduction was observed between grade I group and healthy individuals (P = 0.0001), also a significant lower value of HDL-C was observed between healthy individuals, grade I (P = 4.9E-8), grade II (P = 0.00005) and grade III (P = 0.039) groups (Table 2). To understand whether the values of lipid profile differ with healthy individuals depending on the site of tumour, we divided patients into different groups based on the tumour location and compared the serum lipid profile of these groups with controls, the obtained results are shown in Table 3, for instance lower triglyceride levels in OSCC patients compared to control group was significant only in patients with Maxilla (P = 0.022) and oral cavity mucosa tumours (P = 0.019) (See Table 3). Subjects with stage II (P = 0.019), III (P = 0.007) and IV (P = 0.0002) had lower cholesterol level compared to controls; the HDL-C was lower in all the stages I (P = 0.008), II (P = 0.000003), III (P = 0.0001) and IV (P = 0.00001) compared to the healthy individuals; also LDL-C
Fig. 1. Comparison of lipid profile levels between OSCC patients and healthy individuals. (A) Cholesterol, (B) Triglyceride, (C) HDL-C, (D) LDL-C, (E) VLDL. $P < 0.05$ is significant.

Table 2. Comparison of lipid profile and tumour grade between OSCC patients and healthy controls.

| Lipid Profile | Healthy Controls | Grade I | Grade II | Grade III |
|---------------|------------------|---------|----------|-----------|
| Cholesterol   | 164.61 ± 29.11   | 122.54 ± 34.05 | 141.28 ± 25.89 | 136.5 ± 36.06 |
| Triglyceride  | 104.08 ± 31.81   | 79.92 ± 35.05 | 87.57 ± 26.41 | 82.00 ± 26.87 |
| HDL-C         | 47.00 ± 9.50     | 23.61 ± 11.70 | 29.00 ± 9.50 | 32.50 ± 9.20 |
| LDL-C         | 90.58 ± 24.00    | 77.80 ± 23.67 | 88.91 ± 19.45 | 82.18 ± 30.36 |
| VLDL          | 20.81 ± 6.36     | 15.98 ± 7.01  | 17.51 ± 5.28 | 16.40 ± 5.37 |

$p$ value* comparison of lipid profile of OSCC and healthy controls

| Grade | Healthy controls |
|-------|------------------|
| Grade I | 0.0001 | 0.351 | 4.9E-8 | 0.057 | 0.351 |
| Grade II | 0.008 | 0.152 | 0.00005 | 0.388 | 0.152 |
| Grade III | 0.142 | 0.409 | 0.039 | 0.563 | 0.409 |

Grade I: Well differentiated carcinoma; Grade II: Moderately differentiated carcinoma; Grade III: Poorly differentiated carcinoma; HDL-C: High density lipoprotein-Cholesterol; LDL-C: Low density lipoprotein-Cholesterol; VLDL: Very low density lipoprotein. $P < 0.05$ is significant.
3.2. Decreased ApoC1 serum concentration in patients with OSCC compared to healthy individuals

In order to investigate the clinical value of ApoC1 serum level, first we compared the serum level of ApoC1 between OSCC patients and controls to see whether it is altered in OSCC or not. As indicated in Fig. 2, the results revealed the significant decrease in serum ApoC1 of OSCC patients as compared to healthy individuals (P = 0.001).

3.3. The serum ApoC1 is not predictive of OSCC staging, grade and tumour size

The observed alteration in ApoC1 serum level of OSCC patients motivated us to examine its correlation with clinical and pathological features of patients. Neither tumour size (P = 0.67) nor grade (P = 0.7) were significantly correlated with serum ApoC1 concentration (Table 5). Interestingly, we found that for patients with vascular invasion, the ApoC1 level is statistically higher than for those without vascular invasion (Fig. 3 and Table 5).

4. Discussion

Lipids play important roles as energy storage, structural component of cell membranes and signaling processes [25,26]. Tumour cells need high level of lipids to fulfill the requirements of cell rapid proliferation and growth, thus exhibit changes in lipid metabolism pathways. To this end, tumour cells show increased lipid uptake, endogenous de novo lipogenesis, oxidation of fatty acids and cholesterol accumulation [27]. Lipid

---

**Table 3. Comparison of lipid profile and tumour subsites between OSCC patients and healthy controls.**

| Tumour subsites       | Cholesterol | Triglyceride | HDL-C | LDL-C | VLDL |
|-----------------------|-------------|--------------|-------|-------|------|
| Healthy Controls      | 164.61 ± 29.11 | 104.08 ± 31.81 | 47.00 ± 9.50 | 90.58 ± 24.00 | 20.81 ± 6.36 |
| Oral cavity           | 125.50 ± 0.71 | 48.50 ± 0.71  | 30.50 ± 0.71 | 78.99 ± 1.41  | 8.90 ± 1.27 |
| Tongue                | 115.20 ± 30.62 | 97.20 ± 36.39 | 22.2 ± 11.21 | 68.95 ± 19.90 | 19.44 ± 7.28 |
| Mouth floor           | 125.50 ± 0.71 | 95.50 ± 0.71  | 25.50 ± 0.71 | 74.88 ± 1.24  | 18.60 ± 0.85 |
| Lip/Buccal mucosa     | 131.78 ± 34.15 | 85.00 ± 30.37 | 24.67 ± 6.80 | 84.53 ± 25.34 | 17.00 ± 6.07 |
| Maxilla               | 150.50 ± 23.33 | 49.50 ± 0.71  | 50.00 ± 9.90 | 85.06 ± 12.76 | 9.90 ± 0.14  |
| Mandible              | 155.50 ± 38.12 | 99.50 ± 12.02 | 23.00 ± 8.50 | 105.64 ± 19.65 | 19.9 ± 2.40 |
| Palate                | 114.50 ± 50.20 | 61.00 ± 31.11 | 19.50 ± 9.19 | 77.71 ± 32.64 | 12.20 ± 6.22 |

*p* value* comparison of lipid profile of OSCC and healthy controls

| Tumour subsites       | Cholesterol | Triglyceride | HDL-C | LDL-C | VLDL |
|-----------------------|-------------|--------------|-------|-------|------|
| Oral cavity * Healthy controls | 0.021 | 0.019 | 0.021 | 0.430 | 0.012 |
| Tongue * Healthy controls | 0.001 | 0.881 | 0.000028 | 0.046 | 0.881 |
| Mouth floor * Healthy controls | 0.005 | 0.848 | 0.005 | 0.304 | 0.754 |
| Lip/Buccal mucosa* Healthy controls | 0.004 | 0.215 | 4.9E-7 | 0.413 | 0.215 |
| Maxilla * Healthy controls | 0.991 | 0.022 | 0.991 | 0.668 | 0.022 |
| Mandible* Healthy controls | 0.002 | 0.996 | 0.002 | 0.436 | 0.996 |
| Palate* Healthy controls | 0.001 | 0.079 | 0.001 | 0.409 | 0.079 |

**Table 4. Comparison of lipid profile and tumour stage between OSCC patients and healthy controls.**

| Tumour stage       | Cholesterol | Triglyceride | HDL-C | LDL-C | VLDL |
|--------------------|-------------|--------------|-------|-------|------|
| Healthy Controls   | 164.61 ± 29.11 | 104.08 ± 31.81 | 47.00 ± 9.50 | 90.58 ± 24.00 | 20.81 ± 6.36 |
| Stage I            | 150.33 ± 34.99 | 90.67 ± 24.21 | 31.33 ± 6.81 | 94.63 ± 30.43 | 18.13 ± 4.84 |
| Stage II           | 131.80 ± 35.94 | 82.40 ± 39.93 | 19.80 ± 5.58 | 89.62 ± 23.73 | 16.48 ± 7.98 |
| Stage III          | 131.67 ± 24.28 | 81.33 ± 25.00 | 28.67 ± 6.25 | 81.37 ± 15.63 | 16.27 ± 5.00 |
| Stage IV           | 111.17 ± 33.23 | 74.33 ± 24.83 | 22.17 ± 11.63 | 69.54 ± 24.75 | 14.87 ± 4.97 |

*p* value* comparison of lipid profile of OSCC and healthy controls

| Tumour stage       | Cholesterol | Triglyceride | HDL-C | LDL-C | VLDL |
|--------------------|-------------|--------------|-------|-------|------|
| Stage I* Healthy controls | 0.327 | 0.613 | 0.008 | 0.874 | 0.613 |
| Stage II* Healthy controls | 0.019 | 0.267 | 0.00003 | 0.816 | 0.267 |
| Stage III* Healthy controls | 0.007 | 0.165 | 0.0001 | 0.284 | 0.165 |
| Stage IV* Healthy controls | 0.0002 | 0.058 | 0.00001 | 0.043 | 0.058 |

HDL-C: High density lipoprotein-Cholesterol; LDL-C: Low density lipoprotein-Cholesterol; VLDL: Very low density lipoprotein. P < 0.05 is significant.

was lower only in stage IV compared to controls (P = 0.043) (See Table 4).
metabolism deregulation is one of the cancer hallmarks and has been considered as promising therapeutic targets [27]. For instance, the overexpression of Fatty Acid Synthase (FASN) which is a key lipogenic enzyme has been reported to be associated with proliferation, chemoresistance and poor prognosis of ovarian cancer and FASN inhibitors have been shown to promote cancer cell apoptosis [28]. Therefore, the decrease in blood lipids in some cancers can be due to the effects of cancer cells’ metabolism, disruption of the metabolic pathways of lipids, increased lipid peroxidation and antioxidant vitamins. To compensate for their lipid deficiency, cancer cells increase the lipogenesis or meet the need for the breakdown of blood lipoproteins such as HDL-C, LDL-C and VLDL [7]. Lipoproteins are in charge of delivering endogenous and exogenous lipids to the tissues [29]. ApoC-1 as a surface component of lipoproteins including chylomicron, HDL and LDL is mainly expressed in liver and its oncogenic role has been reported in pancreatic, breast and lung cancer [18,30,31]. Several studies declared that ApoC-1 mediates cell survival and the knockdown of ApoC-1 significantly has decreased proliferation of pancreatic cancer cells and induced apoptosis [18]. This study aimed at investigating both the serum lipid profile and ApoC-1 levels in OSCC patients and healthy individuals. We confirm the findings of previous studies on lower serum lipid profile values including TG, cholesterol, HDL-C, LDL-C and VLDL of OSCC patients compared to the controls [4,25]. Except to HDL-C, we found a progressive decline in all lipid profile values as stage increases. Additionally, the serum mean value of cholesterol compared to healthy individuals is significant only for stage III and stage IV. Regarding the histopathological grades, among all measured lipids only cholesterol decreases as grade increases. This is the first report that provide evidence on the significant differences of serum ApoC-1 between OSCC and healthy individuals. We found the lower serum ApoC-1 level in OSCC compared to the healthy individuals whereas Song et al. recently found that the serum level of ApoC-1 was

Table 5. Correlation of ApoC1 with clinicopathological features of OSCC patients.

| Sample Size | Groups | ApoC1 |
|-------------|--------|-------|
| Tumour Stage 20 | Stage I (n = 3), Stage II (n = 5), Stage III (n = 6), Stage IV (n = 6) | ANOVA pval = 0.989 |
| Tumour Grade 22 | – | Pearson’s corr. coef. = 0.08, pval = 0.7 |
| Tumour Size 20 | – | Pearson’s corr. coef. = −0.095, pval = 0.673 |
| Tumour Subsites 22 | Oral cavity (n = 2), Tongue (n = 5), Mouth floor (n = 2), Lip/Buccal mucosa (n = 9), Maxilla (n = 2), Mandible (n = 2) | ANOVA pval = 0.13 |
increased in patients with TNBC compared to non-TNBC [30]. On the other hand, Li and colleagues reported reduction of serum ApoC-1 level of pancreatic cancer patients after surgery compared to the preoperative serum confirming that pancreatic cancer cells secrete ApoC-1 [18]. To unravel the reason behind lower serum level of ApoC-1 in OSCC patients compared to the healthy individuals, one need to investigate and compare the ApoC-1 tumour expression with normal oral mucosa tissue. The OSCC patients with vascular invasion showed significantly higher ApoC-1 level as compared to those without invasion. Neither grade nor stage was associated with significant decrease of serum ApoC-1 level. Taking into account the location of studied malignancy, saliva ApoC-1 is more relevant than serum and the recent work by Hirtz et al. on saliva revealed that ApoC-1 upregulated in OSCC without lymph node metastasis vs. OSCC_FREE and OSCC with lymph node metastasis [32]. A future study to measure ApoC-1 on saliva, serum and tissue of the same OSCC patients and comparing it with healthy individuals is needed.

5. Conclusion

Decreased lipid profile and ApoC-1 levels in our study may indicate a correlation between these factors and the progression of OSCC. The main limitation of this study was the evaluation of ApoC-1 in the serum and tumour tissue of the same patients which could potentially enable us to hypothesize whether OSCC tissue expresses and secretes ApoC-1 in the serum or not. Additionally, since the apolipoprotein E (ApoE) and ApoC-1 genes belong to the same gene cluster, it would be very informative to correlate the decrease in plasma cholesterol with apoE in future research. Further investigation to unravel its prognostic importance is needed and would potentially lead to a new therapeutic target for OSCC patients.

Acknowledgements

This article has been extracted from the thesis written by Ms. Walaa Alazzawi (Registration No.:233).

Funding

Not applicable.

Conflict of interest

The authors declare no competing interest.

References

[1] Sasahira T, Kiriti T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma. Int J Mol Sci 2018;19.
[2] Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res 2020; 9:229.
[3] Feller I, Lemmer J. Oral squamous cell carcinoma: epidemiology, clinical presentation and treatment. 2012.
[4] Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol : Off J Ind Soc Med Paediatr Oncol 2011;32:34–7.
[5] Aylala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014;2014:360458.
[6] Reddy AV, Killampalli LK, Prakash AR, Naag S, Sreenath G, Biragatti SK. Analysis of lipid profile in cancer patients, smokers, and nonsmokers. Dent Res J 2016;13:494.
[7] Notarnicola M, Altomare DF, Correale M, Ruggieri E, D’Attoma B, Mastrosimmini A, et al. Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology 2005;68:210–16.
[8] Zhou Y, Luo G. Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer, vol. 22. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020. p. 1952–62.
[9] JU Onwuka, Oketunke AP, Otutu UA, Akpa OM, Feng R. Lipid profile and risk of ovarian tumours: a meta-analysis. BMC Cancer 2020;20:200.
[10] Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011;48:498–515.
[11] Ren L, Yi J, Li W, Zheng X, Liu J, Wang J, et al. Apolipoproteins and cancer. Cancer Med 2019;8:7032–43.
[12] Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999;19:472–84.
[13] Ki CS, Na DL, Kim DK, Kim HJ, Kim JW. Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer’s disease. Neurosci Lett 2002;319:75–8.
[14] Bus P, Pierneef L, Bor R, Wolterbeek R, van Es LA, Rensen PC, et al. Apolipoprotein C-I plays a role in the pathogenesis of glomerulosclerosis. J Pathol 2017;241:589–99.
[15] Huang S, Qiao J, Li R, Wang L, Li M. Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome? Fertil Steril 2010;94:205–10.
[16] Shi X, Wang J, Dai S, Qin L, Zhou J, Chen Y. Apolipoprotein C1 (APOC1): a novel diagnostic and prognostic biomarker for cervical cancer. Oncotargets Ther 2020;13:12881.
[17] Su WP, Sun LN, Yang SJ, Zhao H, Zeng Ty, Wu W, et al. Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro. J Biochem Mol Toxicol 2018;32:e22158.
[18] Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, et al. Apolipoprotein C-1 demonstrates metabolic abnormality early in women with polycystic ovary syndrome? Fertil Steril 2018;109:439.
[19] Shi X, Wang J, Dai S, Qin L, Zhou J, Chen Y. Apolipoprotein C1 (APOC1): a novel diagnostic and prognostic biomarker for cervical cancer. Oncotargets Ther 2020;13:12881.
[20] Engwegen JY, Depla AC, Smits ME, Cats A, Tuyman H, Van Heuvelen HA, et al. Detection of colorectal cancer by serum and tissue protein profiling: a prospective study in a population at risk. Biomark Insights 2008;3:5790. BMI.
[21] Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang S, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer 2009;8:1–14.

[22] Zhang Q, Wang J, Dong R, Yang S, Zheng S. Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep 2011;38:631–8.

[23] Karkhaneh A, Bagherieh M, Sadeghi S, Kheirollahi A. Evaluation of eight formulas for LDL-C estimation in Iranian subjects with different metabolic health statuses. Lipids Health Dis 2019;18:1–11.

[24] Wilson PW, Abbott RD, Garrison RJ, Castelli WP. Estimation of very-low-density lipoprotein cholesterol from data on triglyceride concentration in plasma. Clin Chem 1981;27:2008–10.

[25] Acharya S, Rai P, Hallikeri K, Anehosur V, Kale J. Serum lipid profile in oral squamous cell carcinoma: alterations and association with some clinicopathological parameters and tobacco use. Int J Oral Maxillofac Surg 2016;45:713–20.

[26] Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012;279:2610–23.

[27] Wang W, Bai L, Li W, Cui J. The lipid metabolic landscape of cancers and new therapeutic perspectives. Front Oncol 2020;10:605154.

[28] Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng J, et al. Deregulation of lipid metabolism: the critical factors in ovarian cancer. Front Oncol 2020;10:593017.

[29] Salter AM, Brindley DN. The biochemistry of lipoproteins. J Inherit Metab Dis 1988;11(Suppl 1):4–17.

[30] Song D, Yue L, Zhang J, Ma S, Zhao W, Guo F, et al. Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Cancer Biol Ther 2016;17:635–47.

[31] Ko HL, Wang YS, Fong WL, Chi MS, Chi KH, Kao SJ. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: a marker phase I trial. Thorac Cancer 2014;5:590–8.

[32] Hirtz C, Vialaret J, Nowak N, Gabelle A, Deville de Périere D, Lehmann S. Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. Bioanalysis 2016;8:43–53.